Answers are grounded in this paper and cite their sources.
Network meta-analysis shows glucagon receptor agonists improve outcomes in obesity and T2DM, indicating acceptable safety.
Retatrutide and survodutide exhibit the most favourable efficacy profiles for obesity and T2DM, with acceptable safety. These findings support their potential clinical use and highlight the need for future head-to-head trials.
No takes yet. Share an insight, caveat, or question.
Abulehia et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: